Literature DB >> 18763430

Adverse effects of ropinirole-treated restless leg syndrome (RLS) during smoking cessation.

Timothy M Juergens1.   

Abstract

The impact of nicotine on drug metabolism should be carefully considered, including its impact on ropinirole. The author presents a case in which a patient with RLS effectively treated with ropinirole (Requip) experienced profound side effects from ropinirole when she stopped smoking.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18763430      PMCID： PMC2542495     

Source DB:  PubMed          Journal:  J Clin Sleep Med        ISSN： 1550-9389            Impact factor:   4.062


  1 in total

1.  Restless legs syndrome prevalence and impact: REST general population study.

Authors:  Richard P Allen; Arthur S Walters; Jacques Montplaisir; Wayne Hening; Andrew Myers; Timothy J Bell; Luigi Ferini-Strambi
Journal:  Arch Intern Med       Date:  2005-06-13
  1 in total
  3 in total

Review 1.  Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products.

Authors:  Gail D Anderson; Lingtak-Neander Chan
Journal:  Clin Pharmacokinet       Date:  2016-11       Impact factor: 6.447

2.  Increased Risk for New-Onset Psychiatric Adverse Events in Patients With Newly Diagnosed Primary Restless Legs Syndrome Who Initiate Treatment With Dopamine Agonists: A Large-Scale Retrospective Claims Matched-Cohort Analysis.

Authors:  Cheryl Hankin; Daniel Lee; Diego Garcia-Borreguero; Zhaohui Wang
Journal:  J Clin Sleep Med       Date:  2019-09-15       Impact factor: 4.062

3.  Impact of switching to a heat-not-burn tobacco product on CYP1A2 activity.

Authors:  Angela van der Plas; Sandrine Pouly; Nicolas Blanc; Christelle Haziza; Guillaume de La Bourdonnaye; Bjorn Titz; Julia Hoeng; Nikolai V Ivanov; Brindusa Taranu; Annie Heremans
Journal:  Toxicol Rep       Date:  2020-10-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.